Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound docetaxel plus nivolumab in platinum-progressed recurrent or metastatic head and neck squamous cell carcinoma
CTR20212027Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Mar 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of docetaxel and nivolumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Mar 2022; status: active.
02
Drugs
docetaxelnivolumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20212027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212027.